Short radiation followed by chemo plus bevacizumab with or without immunotherapy for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of colon cancer called rectal adenocarcinoma that has not been treated yet.
- Your tumor must not have a BRAF mutation or be MSI-H (high microsatellite instability).
- You cannot have severe bowel blockage or cancer that has spread to other organs.
- Your rectal MRI must show locally advanced cancer (T3c-d or T4, or positive lymph nodes, or other high-risk features).
- You must be between 18 and 75 years old and in good enough health to walk and care for yourself (ECOG 0-1).
- Your blood counts and liver/kidney function must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of chemotherapy, radiation, and two newer drugs (an immunotherapy and an anti-angiogenesis drug) before surgery can improve outcomes for people with locally advanced rectal cancer. If you qualify, you would receive this treatment for a few months, and then have surgery.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.